Methods and compositions for diagnosis and treatment of cancer

Patent metadata

Field	Value
Publication number	US-11473085-B2
Application number	US-201916275111-A
Country	US
Kind code	B2
Filing date	Feb 13, 2019
Priority date	Feb 20, 2009
Publication date	Oct 18, 2022
Grant date	Oct 18, 2022

Abstract

The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.

First claim

The invention claimed is:

1. A method of treating a patient having a tumor disease that expresses a tumor antigen encoded by a nucleic acid sequence according to SEQ ID NO: 1 or a variant of said nucleic acid sequence,
wherein the method comprises administering to the patient a pharmaceutical composition comprising an antibody that specifically binds a tumor antigen encoded by a nucleic acid according to SEQ ID NO: 1, wherein the tumor disease is a testicular cancer.

2. The method of claim 1 , wherein the antibody is a monoclonal, chimeric, human or humanized antibody, or is an antigen binding fragment of an antibody or a synthetic antibody.

3. The method of claim 1 , wherein the antibody is a monoclonal, chimeric, human or humanized antibody.

4. The method of claim 1 , wherein the antibody is attached to one or more therapeutic effector moieties selected from the group consisting of a radiolabel, cytotoxin, and cytotoxic enzyme.

5. The method of claim 1 , wherein the testicular cancer is selected from the group consisting of germ cell tumors, testicular seminoma, testicular teratoma, embryonic testicular cancer, and testicular embryonal carcinoma.

6. A method of treating a patient who has been diagnosed with a tumor disease associated with a tumor antigen comprising an amino acid sequence encoded by a nucleic acid sequence of SEQ ID NO: 1 or a variant of said nucleic acid sequence,
wherein the method comprises administering to the patient a pharmaceutical composition comprising an antibody that specifically binds a tumor antigen encoded by a nucleic acid according to SEQ ID NO: 1, wherein the tumor disease is a testicular cancer.

7. The method of claim 6 , wherein the antibody is a monoclonal, chimeric, human or humanized antibody, or is an antigen binding fragment of an antibody or a synthetic antibody.

8. The method of claim 6 , wherein the antibody is a monoclonal, chimeric, human or humanized antibody.

9. The method of claim 6 , wherein the antibody is attached to one or more therapeutic effector moieties selected from the group consisting of a radiolabel, cytotoxin, and cytotoxic enzyme.

10. The method of claim 6 , wherein the testicular cancer is selected from the group consisting of germ cell tumors, testicular seminoma, testicular teratoma, embryonic testicular cancer, and testicular embryonal carcinoma.

Assignees

• Ganymed Pharmaceuticals Ag
• Univ Mainz Johannes Gutenberg
• Ganymed Pharmaceuticals Gmbh

Inventors

• Sahin Ugur
• Tureci Özlem
• Koslowski Michael
• Helftenbein Gerd
• Walter Korden
• Woll Stefan
• Oprea Gabriela-Elena

Classifications

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• G01N33/57545 Primary

  of the ovaries · CPC title

• G01N33/5752

  of the lungs · CPC title

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• A61K31/7088 Primary

  Compounds having three or more nucleosides or nucleotides · CPC title